Frontiers in Clinical Drug Research – Dementia is a book series which presents comprehensive reviews about research on Dementia, a term which references the loss of brain function associated with Alzheimer’s disease and other related medical conditions. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of disease development and the cure for dementia and related disorders.
The first volume includes the following reviews:
- Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer’s Disease
- Cholesterol in Brain Health and Pathologies
- Advances in the Treatment of Mild Cognitive Impairment (MCI) and Dementia
- Analytical Methods in Alzheimer’s Disease Drug Discovery
- Targeting Alzheimer’s Disease through Nanomedicine
- Current Challenges in Alzheimer’s Disease Research
- Metals Linked to Alzheimer’s Disease
This book can serve as a reference for neurologists, medical specialists (neurophysicians, psychiatrists), pharmacologists, pharmacists, researchers and postgraduate students in nanomedicine.
About the Editor:
Prof. Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1080 international publications in several fields of organic chemistry including 751 research publications, 37 international patents, 69 chapters in books and 221 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world’s leading encyclopedic series of volumes on natural products ‘Studies in Natural Product Chemistry’ 54 volumes of which have been published under his Editorship by Elsevier during the last two decades.
Prof. Rahman won the UNESCO Science Prize (1999) and was elected as Fellow of the prestigious Royal Society (London) in July 2006. He has been conferred honorary doctorate degrees by many universities including (Sc.D.) by the Cambridge University (UK) (1987). He was elected Honorary Life Fellow of Kings College, Cambridge University, UK, conferred the TWAS (Italy) Prize and the Austrian government has honored him with its high civil award (“Grosse Goldene Ehrenzeischen am Bande”) (2007). He is Foreign Fellow of Chinese and Korean Academy of Sciences, Foreign Fellow of the Chinese Chemical Society and former President of Pakistan Academy of Sciences.
Alzheimer’s Disease, Nanomedicine, Mild Cognitive Impairment (MCI), Dementia, Analytical Methods, Drug Discovery, neurologists
For further information, please visit:
Faizan ul Haq